PAHC
Phibro Animal Health Corporation
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$33.05-0.78%
Price as of Jul 20, 2026
PAHC financials
Phibro Animal Health Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.3B | $1.0B | $977.9M | $942.3M |
| Cost of revenue | $896.3M | $704.6M | $679.7M | $656.9M |
| Gross profit | $399.9M | $313.1M | $298.2M | $285.4M |
| Operating expenses | $289.5M | $259.8M | $226.4M | $206.4M |
| Operating income | $110.5M | $53.3M | $71.8M | $79.0M |
| Net income | $48.3M | $2.4M | $32.6M | $49.2M |
| EBITDA | $146.8M | $69.1M | $106.0M | $117.1M |
| Basic EPS | $1.19 | $0.06 | $0.81 | $1.21 |
| Diluted EPS | $1.19 | $0.06 | $0.81 | $1.21 |
| Balance sheet | ||||
| Cash & equivalents | $68.0M | $70.6M | $41.3M | $74.2M |
| Total assets | $1.4B | $982.2M | $971.4M | $931.7M |
| Total liabilities | $1.1B | $725.5M | $688.9M | $669.3M |
| Stockholders’ equity | $285.7M | $256.6M | $282.5M | $262.4M |
| Total debt | $761.6M | $525.5M | $510.0M | $470.5M |
| Net debt | $693.5M | $454.8M | $468.7M | $396.2M |
| Cash flow | ||||
| Operating cash flow | $80.1M | $87.6M | $13.3M | $31.6M |
| Capital expenditure | -$38.3M | -$41.2M | -$51.8M | -$37.0M |
| Free cash flow | $41.8M | $46.4M | -$38.5M | -$5.4M |
| Dividends paid | -$19.4M | -$19.4M | -$19.4M | -$19.4M |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |